Pharm-Olam, a global mid-sized CRO, has been selected by the U.S. Department of Defense to build capability at military treatment facilities in order to support Phase III clinical trials of one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed. The CRO will provide project management, contract management, and clinical trial site support to participating military treatment facility investigative sites. Pharm-Olam will be partnering with The Geneva Foundation, whi...